000 | 03500cam a2200769Ma 4500 | ||
---|---|---|---|
001 | ocn757827332 | ||
003 | OCoLC | ||
005 | 20171224113727.0 | ||
006 | m o d | ||
007 | cr |n||||||||| | ||
008 | 111017s2011 njuaf ob 001 0 eng d | ||
040 |
_aYDXCP _beng _epn _cYDXCP _dUIU _dE7B _dN$T _dTEF _dOCLCQ _dNLGGC _dDEBSZ _dMHW _dUKDOC _dOCLCQ _dCOO _dOCLCQ |
||
019 |
_a811493902 _a961689382 _a962723516 |
||
020 |
_a9781118015377 _q(electronic bk.) |
||
020 |
_a1118015371 _q(electronic bk.) |
||
020 |
_a9781118015353 _q(electronic bk.) |
||
020 |
_a1118015355 _q(electronic bk.) |
||
020 |
_z9780470184745 _q(cloth) |
||
020 |
_z0470184744 _q(cloth) |
||
020 | _z9781118015360 | ||
024 | 7 |
_a10.1002/9781118015377 _2doi |
|
029 | 1 |
_aAU@ _b000053283776 |
|
029 | 1 |
_aDEBSZ _b430992017 |
|
029 | 1 |
_aDKDLA _b820120-katalog:000582681 |
|
029 | 1 |
_aNZ1 _b14692240 |
|
029 | 1 |
_aDEBBG _bBV043393613 |
|
035 |
_a(OCoLC)757827332 _z(OCoLC)811493902 _z(OCoLC)961689382 _z(OCoLC)962723516 |
||
050 | 4 |
_aQR201.A37 _bH547 2011eb |
|
060 | 4 | _aQV 268.5 | |
072 | 7 |
_aHEA _x039020 _2bisacsh |
|
072 | 7 |
_aMED _x022020 _2bisacsh |
|
082 | 0 | 4 |
_a616.97/9201 _222 |
049 | _aMAIN | ||
245 | 0 | 0 |
_aHIV-1 integrase : _bmechanism and inhibitor design / _c[edited] by Nouri Neamati. |
260 |
_aHoboken, N.J. : _bWiley, _c©2011. |
||
300 |
_a1 online resource (xiii, 506 pages, [16] pages of plates) : _billustrations (some color). |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
490 | 1 | _aWiley series in drug discovery and development | |
588 | 0 | _aPrint version record. | |
504 | _aIncludes bibliographical references and index. | ||
520 | _aThis book comprehensively covers the mechanisms of action and inhibitor design for HIV-1 integrase. It serves as a resource for scientists facing challenging drug design issues and researchers in antiviral drug discovery. Despite numerous review articles and isolated book chapters dealing with HIV-1 integrase, there has not been a single source for those working to devise anti-AIDS drugs against this promising target. But this book fills that gap and offers a valuable introduction to the field for the interdisciplinary scientists who will need to work together to design drugs that target HIV-1. | ||
650 | 0 |
_aHIV (Viruses) _xEnzymes. |
|
650 | 0 |
_aHIV (Viruses) _xEnzymes _xInhibitors. |
|
650 | 0 | _aAntiviral agents. | |
650 | 2 |
_aHIV Integrase Inhibitors _xpharmacology. |
|
650 | 2 | _aDrug Design. | |
650 | 2 | _aHIV Integrase. | |
650 | 4 | _aAntiviral agents. | |
650 | 4 |
_aHIV (Viruses) _xEnzymes _xInhibitors. |
|
650 | 4 |
_aHIV (Viruses) _xEnzymes. |
|
650 | 7 |
_aHEALTH & FITNESS _xDiseases _xAIDS & HIV. _2bisacsh |
|
650 | 7 |
_aMEDICAL _xAIDS & HIV. _2bisacsh |
|
655 | 4 | _aElectronic books. | |
700 | 1 |
_aNeamati, Nouri. _4edt |
|
776 | 0 | 8 |
_iPrint version: _tHIV-1 integrase. _dHoboken, N.J. : Wiley, ©2011 _z9780470184745 _z0470184744 _w(DLC) 2010043285 _w(OCoLC)670176130 |
830 | 0 | _aWiley series in drug discovery and development. | |
856 | 4 | 0 |
_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118015377 _zWiley Online Library |
938 |
_a123Library _b123L _n20102 |
||
938 |
_aebrary _bEBRY _nebr10494542 |
||
938 |
_aEBSCOhost _bEBSC _n391368 |
||
938 |
_aYBP Library Services _bYANK _n3537284 |
||
938 |
_aYBP Library Services _bYANK _n3588110 |
||
938 |
_aYBP Library Services _bYANK _n7146971 |
||
994 |
_a92 _bDG1 |
||
999 |
_c11334 _d11334 |